Your browser doesn't support javascript.
loading
Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study.
Yang, Yi; Zhou, Yanzhao; Zhang, Xinyuan; Xin, Yujing; Chen, Yi; Fan, Qingsheng; Li, Xiao; Wei, Xi; Li, Qiang; Zhou, Xiang; Zhou, Jinxue.
Affiliation
  • Yang Y; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
  • Zhou Y; Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan Province, People's Republic of China.
  • Zhang X; Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China.
  • Xin Y; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
  • Chen Y; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
  • Fan Q; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
  • Li X; Department of Interventional Radiology, First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi Province, People's Republic of China.
  • Wei X; Department of Oncology, Capital Medical University Affiliated Beijing Hospital of Traditional Chinese Medicine, Beijing, 100010, People's Republic of China.
  • Li Q; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
  • Zhou X; Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of Chin
  • Zhou J; Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China.
J Hepatocell Carcinoma ; 8: 837-850, 2021.
Article in En | MEDLINE | ID: mdl-34350139
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: J Hepatocell Carcinoma Year: 2021 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: J Hepatocell Carcinoma Year: 2021 Type: Article